185 related articles for article (PubMed ID: 36243499)
21. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
22. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
23. Nuclear medicine in NET.
Sorschag M; Malle P; Gallowitsch HJ
Wien Med Wochenschr; 2012 Oct; 162(19-20):416-22. PubMed ID: 22810487
[TBL] [Abstract][Full Text] [Related]
24. Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of Their Disease.
Mennetrey C; Le Bras M; Bando-Delaunay A; Al-Mansour L; Haissaguerre M; Batisse-Lignier M; Ouvrard E; Ansquer C; Walter T; de Mestier L; Kelly A; Tlili G; Giraud S; North MO; Odou MF; Goichot B; Cuny T; Loundou A; Romanet P; Imperiale A; Taïeb D
J Clin Endocrinol Metab; 2022 Apr; 107(5):e2056-e2064. PubMed ID: 34940846
[TBL] [Abstract][Full Text] [Related]
25. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
[TBL] [Abstract][Full Text] [Related]
26. State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging.
Carollo A; Papi S; Grana CM; Mansi L; Chinol M
Curr Radiopharm; 2019; 12(2):107-125. PubMed ID: 30843499
[TBL] [Abstract][Full Text] [Related]
27. Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, and Pitfalls.
Yu R; Wachsman A
Endocrinol Metab Clin North Am; 2017 Sep; 46(3):795-814. PubMed ID: 28760239
[TBL] [Abstract][Full Text] [Related]
28. Theranostics in Neuroendocrine Tumors.
Mallak N; O'Brien SR; Pryma DA; Mittra E
Cancer J; 2024 May-Jun 01; 30(3):185-193. PubMed ID: 38753753
[TBL] [Abstract][Full Text] [Related]
29. PET/MRI imaging in neuroendocrine neoplasm.
Virarkar MK; Montanarella M; Itani M; Calimano-Ramirez L; Gopireddy D; Bhosale P
Abdom Radiol (NY); 2023 Dec; 48(12):3585-3600. PubMed ID: 36525051
[TBL] [Abstract][Full Text] [Related]
30. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
31. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.
Barrio M; Czernin J; Fanti S; Ambrosini V; Binse I; Du L; Eiber M; Herrmann K; Fendler WP
J Nucl Med; 2017 May; 58(5):756-761. PubMed ID: 28082438
[TBL] [Abstract][Full Text] [Related]
32. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
33. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
34. Contemporary nuclear medicine imaging of neuroendocrine tumours.
Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
[TBL] [Abstract][Full Text] [Related]
35. Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide.
Zalom ML; Waxman AD; Yu R; Lee J; Ih G; Wolin EM
Endocr Pract; 2009; 15(6):521-7. PubMed ID: 19491080
[TBL] [Abstract][Full Text] [Related]
36. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
Kaemmerer D; Wirtz RM; Fischer EK; Hommann M; Sänger J; Prasad V; Specht E; Baum RP; Schulz S; Lupp A
Pancreas; 2015 May; 44(4):648-54. PubMed ID: 25872131
[TBL] [Abstract][Full Text] [Related]
37. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
38. Molecular imaging of gastroenteropancreatic neuroendocrine tumors.
Miederer M; Weber MM; Fottner C
Gastroenterol Clin North Am; 2010 Dec; 39(4):923-35. PubMed ID: 21093764
[TBL] [Abstract][Full Text] [Related]
39. Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.
Grawe F; Ebner R; Geyer T; Beyer L; Winkelmann M; Sheikh GT; Eschbach R; Schmid-Tannwald C; Cyran CC; Ricke J; Bartenstein P; Heimer MM; Faggioni L; Spitzweg C; Fabritius MP; Auernhammer CJ; Ruebenthaler J
Eur Radiol; 2023 May; 33(5):3416-3424. PubMed ID: 36964768
[TBL] [Abstract][Full Text] [Related]
40. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Hicks RJ
Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]